Document is current
Any future updates will be listed below
-
Authors
Stærke, Nina Breinholt https://orcid.org/0000-0002-5834-2033
Reekie, Joanne https://orcid.org/0000-0001-8529-3559
Nielsen, Henrik
Benfield, Thomas https://orcid.org/0000-0003-0698-9385
Wiese, Lothar
Knudsen, Lene Surland
Iversen, Mette Brouw
Iversen, Kasper
Fogh, Kamille
Bodilsen, Jacob
Juhl, Maria Ruwald
Lindvig, Susan Olaf
Øvrehus, Anne
Madsen, Lone Wulff
Klastrup, Vibeke
Andersen, Sidsel Dahl
Juhl, Anna Karina
Andreasen, Signe Rode
Ostrowski, Sisse Rye https://orcid.org/0000-0001-5288-3851
Erikstrup, Christian https://orcid.org/0000-0001-6551-6647
Fischer, Thea K. https://orcid.org/0000-0003-4812-980X
Tolstrup, Martin
Østergaard, Lars
Johansen, Isik Somuncu
Lundgren, Jens https://orcid.org/0000-0001-8901-7850
Søgaard, Ole Schmeltz https://orcid.org/0000-0001-9107-2023
- License Information
-
More Information
Article History
Received: 4 April 2022
Accepted: 21 July 2022
First Online: 1 August 2022
Competing interests
: H.N. declares participation on advisory board meeting with G.S.K. and M.S.D. T.B. declares receipt of unrestricted research or travel grants from GSK, Pfizer, Gilead Sciences, MSD; and being principal investigator on trials conducted by Boehringer Ingelheim, Roche, Novartis, Kancera, Pfizer, MSD and Gilead; Board member on Pentabase, and advisory board member for MSD, Gilead, Pfizer, GSK, Janssen and AstraZeneca; consulting fees from GSK and Pfizer; receiving donation of study drug from Eli Lilly; and receiving honorarium for lectures from GSK, Pfizer, Gilead Sciences, Boehringer Ingelheim, Abbvie and AstraZeneca. NS declares being principal investigator on studies conducted by Pfizer and Gilead. All other authors declare no competing interests.
